ISIN:SE0009320278

Hemcheck has received a follow up order from its French distributor

Retrieved on: 
Friday, February 3, 2023
Hope, Medical device, Distribution (marketing)

SOLNA, Sweden, Feb. 3, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its French distributor, Eurobio Scientific, corresponding to approximately SEK 80,000.

Key Points: 
  • SOLNA, Sweden, Feb. 3, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its French distributor, Eurobio Scientific, corresponding to approximately SEK 80,000.
  • The order concerns instruments for diagnostic use.
  • - We have a positive trend in terms of sales, which is very positive.
  • We hope and believe we will get more similar orders, says Joen Averstad, CEO of Hemcheck.

Hemcheck has received a follow up order from its UK distributor

Retrieved on: 
Wednesday, February 1, 2023
CLS, Medical device, Pharmaceutical industry

SOLNA, Sweden, Feb. 1, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its UK distributor, CLS.

Key Points: 
  • SOLNA, Sweden, Feb. 1, 2023 /PRNewswire/ -- Hemcheck has received a follow-up order from its UK distributor, CLS.
  • The order concerns instruments for diagnostic use and bgs-Tests and is of smaller economic value.
  • - Orders continue to come in, which is very positive.
  • It is mainly products for diagnostic use that show good potential and as the British market is very large, we hope for more orders from there, says Joen Averstad, CEO of Hemcheck.

Hemcheck has received a first order from a leading hospital in Iceland

Retrieved on: 
Tuesday, January 24, 2023
News, Whaling, Nursing, Management, Landspítali

SOLNA, Sweden, Jan. 24, 2023 /PRNewswire/ -- Hemcheck has received a first order from Landspitali, the leading university hospital in Iceland.

Key Points: 
  • SOLNA, Sweden, Jan. 24, 2023 /PRNewswire/ -- Hemcheck has received a first order from Landspitali, the leading university hospital in Iceland.
  • The order is a first test order regarding both v-Test and bgs-Test and is of lower economic value.
  • - It is very positive news that we have received this first order from Landspitali.
  • It is a reputable hospital and we hope for more orders from them, says Joen Averstad, CEO of Hemcheck.

Hemcheck extends agreement regarding previously communicated project with Region Skåne

Retrieved on: 
Tuesday, January 3, 2023
Hemolysis, Certification

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.

Key Points: 
  • Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.
  • The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.
  • Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions.
  • By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs.

Hemcheck has received a follow up order from its Irish distributor

Retrieved on: 
Tuesday, December 20, 2022
Hemolysis, Certification

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.

Key Points: 
  • Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.
  • The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.
  • Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions.
  • By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs.

Hemcheck has received an important follow up order from Deutsches Herzzentrum Berlin

Retrieved on: 
Wednesday, December 7, 2022
Certification, Hemolysis

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.

Key Points: 
  • Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.
  • The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.
  • Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions.
  • By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs.

Hemcheck receives additional follow up order from its Greek distributor

Retrieved on: 
Monday, November 28, 2022
Hemolysis, Certification

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.

Key Points: 
  • Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.
  • The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.
  • Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions.
  • By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs.

Hemcheck receives follow up order from its Italian distributor

Retrieved on: 
Wednesday, November 23, 2022
Hemolysis, Certification

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.

Key Points: 
  • Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.
  • The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.
  • Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions.
  • By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs.

Distribution agreement signed for the Italian market

Retrieved on: 
Friday, November 11, 2022
Hemolysis, Certification, Nasdaq

The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.

Key Points: 
  • The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.
  • Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions.
  • Hemcheck's goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient.
  • The company is listed on the Nasdaq First North Growth Market.

Hemcheck receives follow up order from Czech distributor

Retrieved on: 
Thursday, November 10, 2022
Hemolysis, Nasdaq, Certification

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.

Key Points: 
  • Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection.
  • The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes.
  • Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions.
  • By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs.